Clinical characteristics of patients with CLL studied
. | Before Tx . | . | . | . | . | . | Tx response . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sex/age, y . | IgVH status . | Cytogenetics/FISH . | RAI at Tx . | Mo to Tx . | Blood count before Tx . | Blood count after Tx . | Bone marrow after Tx . | Adenopathy before and after Tx . | Spleen CT before/after Tx, cm . | ||||||||
| CLL 15 | M/58 | Unmutated VH1-69 | del 13q, del 6q, del 11q | IV | 28 | ALC 388 × 109/L, Hb 138 g/L, plts 93 × 109/L | ALC 2 × 109/L, Hb 152 g/L, plts 78 × 109/L | Hypercellular, 9% lymphocytes | Clinically resolved, CT > 50% ↓ | 16/13 | ||||||||
| CLL 39 | M/83 | Mutated VH4-61 | del 13q | II | 115 | ALC 82 × 109/L, Hb 130 g/L, plts 133 × 109/L | ALC 5 × 109/L, Hb 125 g/L, plts 118 × 109/L | ND | Clinically and CT resolved | 14/12 | ||||||||
| CLL 55 | M/81 | Unmutated VH1-02 | + 12, del 11q | III | 14 | ALC 225 × 109/L, Hb 94 g/L, plts 130 × 109/L | ALC 8 × 109/L, Hb 128 g/L, plts 146 × 109/L | ND | Clinically resolved, CT > 50% ↓ | 18/14 | ||||||||
| CLL 62 | F/50 | Unmutated VH5-51 | del 13q, del 11q | II | 43 | ALC 115 × 109/L, Hb 135 g/L, plts 269 × 109/L | ALC 7 × 109/L, Hb 138 g/L, plts 171 × 109/L | Normocellular, 45% lymphocytes | Clinically resolved, CT > 50% ↓ | 13/10 | ||||||||
| CLL 52 | M/54 | Unmutated VH2-05 | t(1;14)(p32;q22) | II | 27 | ALC 161 × 109/L, Hb 119 g/L, plts 160 × 109/L | ALC 5 × 109/L, Hb 137 g/L, plts 201 × 109/L | Hypercellular, 95% lymphocytes | Clinically resolved CT > 50% ↓ | 16/14 | ||||||||
| CLL 45 | M/43 | Unmutated VH3-30 | +12 | III | 5 | ALC 124 × 109/L, Hb 69 g/L, plts 170 × 109/L | ALC 7 × 109/L, Hb 77 g/L, plts 88 × 109/L (AIHA) | Normocellular, 50% lymphocytes | Clinically and CT > 50% ↓ | 21/17 | ||||||||
| CLL 50 | M/56 | Unmutated VH3-39 | +12, del 11q | II | 27 | ALC 17 × 109/L, Hb 125 g/L, plts 57 × 109/L | ALC 1 × 109/L, Hb 142 g/L, plts 97 × 109/L | Hypocellular, lymphoid nodules | Clinically and CT resolved | 23/16 | ||||||||
| CLL 31 | F/77 | Mutated VH3-23 | del 13q | II | 10 | NA | NA | NA | NA | NA | ||||||||
| CLL 53 | F/46 | Mutated VH3-33 | del 13q | NA, stable | NA | NA | NA | NA | NA | NA | ||||||||
. | Before Tx . | . | . | . | . | . | Tx response . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sex/age, y . | IgVH status . | Cytogenetics/FISH . | RAI at Tx . | Mo to Tx . | Blood count before Tx . | Blood count after Tx . | Bone marrow after Tx . | Adenopathy before and after Tx . | Spleen CT before/after Tx, cm . | ||||||||
| CLL 15 | M/58 | Unmutated VH1-69 | del 13q, del 6q, del 11q | IV | 28 | ALC 388 × 109/L, Hb 138 g/L, plts 93 × 109/L | ALC 2 × 109/L, Hb 152 g/L, plts 78 × 109/L | Hypercellular, 9% lymphocytes | Clinically resolved, CT > 50% ↓ | 16/13 | ||||||||
| CLL 39 | M/83 | Mutated VH4-61 | del 13q | II | 115 | ALC 82 × 109/L, Hb 130 g/L, plts 133 × 109/L | ALC 5 × 109/L, Hb 125 g/L, plts 118 × 109/L | ND | Clinically and CT resolved | 14/12 | ||||||||
| CLL 55 | M/81 | Unmutated VH1-02 | + 12, del 11q | III | 14 | ALC 225 × 109/L, Hb 94 g/L, plts 130 × 109/L | ALC 8 × 109/L, Hb 128 g/L, plts 146 × 109/L | ND | Clinically resolved, CT > 50% ↓ | 18/14 | ||||||||
| CLL 62 | F/50 | Unmutated VH5-51 | del 13q, del 11q | II | 43 | ALC 115 × 109/L, Hb 135 g/L, plts 269 × 109/L | ALC 7 × 109/L, Hb 138 g/L, plts 171 × 109/L | Normocellular, 45% lymphocytes | Clinically resolved, CT > 50% ↓ | 13/10 | ||||||||
| CLL 52 | M/54 | Unmutated VH2-05 | t(1;14)(p32;q22) | II | 27 | ALC 161 × 109/L, Hb 119 g/L, plts 160 × 109/L | ALC 5 × 109/L, Hb 137 g/L, plts 201 × 109/L | Hypercellular, 95% lymphocytes | Clinically resolved CT > 50% ↓ | 16/14 | ||||||||
| CLL 45 | M/43 | Unmutated VH3-30 | +12 | III | 5 | ALC 124 × 109/L, Hb 69 g/L, plts 170 × 109/L | ALC 7 × 109/L, Hb 77 g/L, plts 88 × 109/L (AIHA) | Normocellular, 50% lymphocytes | Clinically and CT > 50% ↓ | 21/17 | ||||||||
| CLL 50 | M/56 | Unmutated VH3-39 | +12, del 11q | II | 27 | ALC 17 × 109/L, Hb 125 g/L, plts 57 × 109/L | ALC 1 × 109/L, Hb 142 g/L, plts 97 × 109/L | Hypocellular, lymphoid nodules | Clinically and CT resolved | 23/16 | ||||||||
| CLL 31 | F/77 | Mutated VH3-23 | del 13q | II | 10 | NA | NA | NA | NA | NA | ||||||||
| CLL 53 | F/46 | Mutated VH3-33 | del 13q | NA, stable | NA | NA | NA | NA | NA | NA | ||||||||
Tx indicates treatment; IgVH, immunoglobulin gene heavy chain variable region; unmutated, sequence homology of IgVH region > 98% to germ line; del, cytogenetic deletion: ALC, absolute lymphocyte count (normal range, 0.46-4.7 × 109/L [460-4700/μL]); Hb, hemoglobin (normal range, 127-167 g/L [12.7-16.7g/dL] for men, 111-150 g/L (11.1-15 g/dL) for women); Plts, platelet count (normal range, 154-345 × 109/L [154 000-345 000/μL]); CT, computed tomography of relevant disease sites; Mutated, sequence homology of IgVH region < 98% to germ line; ND, not done; AIHA, autoimmune hemolytic anemia; and NA, not applicable.